At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
Aspirin +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Study of the Effect of Combined Treatment of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers
In Brief
A Phase 2 clinical trial evaluating Aspirin, Laboratory Biomarker Analysis, and 2 other interventions for Tobacco Use Disorder. Completed, enrolled 63 participants across 2 sites.
Detailed Summary
This randomized phase II trial studies the effects of aspirin and zileuton on genes related to tobacco use in current smokers. Aspirin and zileuton may interfere with genes related to tobacco use and may be useful in preventing lung cancer in current smokers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartJan 2016
Primary CompletionFeb 2019
Study CompletionMar 2021
TodayJul 2026
First PostedJan 28, 2015
Enrollment StartJan 13, 2016
Primary CompletionFeb 22, 2019
Study CompletionMar 9, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.4 years ago
Interventions
Aspirindrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Placebo Administrationother
Given aspirin placebo PO
Placebo Administrationother
Given zileuton placebo PO
Zileutondrug
Given PO